Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunitybio Inc
(NQ:
IBRX
)
3.950
+0.150 (+3.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunitybio Inc
< Previous
1
2
3
4
5
Next >
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
April 25, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
April 24, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
February 16, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
February 15, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
January 19, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
December 12, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
November 17, 2022
From
ImmunityBio, Inc.
Via
Business Wire
NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer
November 10, 2022
From
ImmunityBio
Via
Business Wire
ImmunityBio to Participate in the Jefferies London Healthcare Conference
October 27, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
July 28, 2022
From
ImmunityBio
Via
Business Wire
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
June 06, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
May 23, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
April 25, 2022
From
ImmunityBio, Inc.
Via
Business Wire
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
April 21, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...
Via
FinancialNewsMedia
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ
April 01, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility
February 15, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
February 14, 2022
From
ImmunityBio, Inc.
Via
Business Wire
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
February 16, 2022
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....
Via
FinancialNewsMedia
Exposures
COVID-19
ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
January 31, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
January 18, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
January 12, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Awarded Seminal Patent on Natural Killer Cells
January 04, 2022
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
December 20, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
November 18, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Present at the Jefferies London Healthcare Conference
November 04, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
October 19, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
October 13, 2021
From
ImmunityBio, Inc.
Via
Business Wire
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
October 04, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
September 13, 2021
From
ImmunityBio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.